OraSure Technologies (NASDAQ:OSUR) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday.

Several other research analysts have also recently issued reports on the company. TheStreet cut OraSure Technologies from a “b” rating to a “c+” rating in a research report on Thursday, November 8th. Zacks Investment Research lowered OraSure Technologies from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. Finally, Raymond James reiterated a “mkt perform” rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $20.50.

Shares of NASDAQ:OSUR opened at $12.63 on Wednesday. The company has a market cap of $774.19 million, a P/E ratio of 24.76, a P/E/G ratio of 3.13 and a beta of 1.54. OraSure Technologies has a 12-month low of $12.27 and a 12-month high of $22.22.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.02. The company had revenue of $45.90 million for the quarter, compared to analysts’ expectations of $44.50 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.49%. OraSure Technologies’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.09 earnings per share. As a group, research analysts forecast that OraSure Technologies will post 0.32 EPS for the current year.

Several large investors have recently added to or reduced their stakes in OSUR. Marshall Wace LLP bought a new stake in shares of OraSure Technologies in the 3rd quarter valued at about $8,489,000. Vanguard Group Inc. raised its position in OraSure Technologies by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,576,389 shares of the medical instruments supplier’s stock valued at $55,256,000 after purchasing an additional 53,671 shares during the last quarter. Morgan Stanley raised its position in OraSure Technologies by 352.3% during the 3rd quarter. Morgan Stanley now owns 1,290,002 shares of the medical instruments supplier’s stock valued at $19,930,000 after purchasing an additional 1,004,774 shares during the last quarter. Legal & General Group Plc raised its position in OraSure Technologies by 9.0% during the 3rd quarter. Legal & General Group Plc now owns 130,950 shares of the medical instruments supplier’s stock valued at $2,030,000 after purchasing an additional 10,861 shares during the last quarter. Finally, Penn Capital Management Co. Inc. raised its position in OraSure Technologies by 583.7% during the 3rd quarter. Penn Capital Management Co. Inc. now owns 710,653 shares of the medical instruments supplier’s stock valued at $11,899,000 after purchasing an additional 606,709 shares during the last quarter. Institutional investors own 92.63% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

See Also: Do stock splits help investors?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.